European Medicines Agency: License Ebola vaccine | Inquirer Technology
Close  

European Medicines Agency recommends licensing Ebola vaccine

/ 05:15 PM October 20, 2019
Ebola

This undated file image made available by the Centers for Disease Control (CDC) shows the Ebola virus. AP

LONDON — The European Medicines Agency has recommended that the world’s first Ebola vaccine be approved, after it was administered to hundreds of thousands of people in Africa.

The agency on Friday described licensing the vaccine as “an important step toward relieving the burden of this deadly disease.”

ADVERTISEMENT

The Ebola vaccine was originally developed in Canada and is now marketed by Merck as Ervebo. More than 270,000 people in Africa have received it as officials try to stop Congo’s ongoing outbreak.

A second vaccine made by Johnson & Johnson, which is not yet licensed, will soon be used in parts of Congo where Ebola is not actively spreading.

FEATURED STORIES

Also Friday, the World Health Organization is convening a meeting to consider whether the epidemic in Congo should still be designated a global emergency. IB/JB

RELATED STORIES:

Second Ebola vaccine to be used in DR Congo next month

Ebola survivors at higher risk of dying, even after recovery

Filipinos in Congo advised to remain cautious amid ebola outbreak

The latest tech news delivered to your inbox

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.
TOPICS: Africa, Congo, ebola, Ebola Virus, Europe, Medical research, vaccines
Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

For feedback, complaints, or inquiries, contact us.

Subscribe to our technology news

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.



© Copyright 1997-2022 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.